|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2004-9-29
|
|
pubmed:abstractText |
Pancreatic adenocarcinoma is among the most aggressively invasive malignancies. The immunoglobulin superfamily member carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is emerging as an important determinant of the malignant phenotype in a range of cancers. We sought to define the role of CEACAM6 in pancreatic adenocarcinoma cellular invasiveness. CEACAM6 was stably overexpressed in Capan2 cells, which inherently express low levels of CEACAM6. Retrovirally mediated RNA interference was used to silence CEACAM6 expression in BxPC3 cells, which inherently overexpress CEACAM6. Cellular invasiveness was quantified using a modified Boyden chamber assay. Overexpression of CEACAM6 increased Capan2 cellular invasiveness, whereas CEACAM6 knockdown attenuated BxPC3 invasiveness. A role for the c-Src tyrosine kinase in mediating CEACAM6-dependent invasiveness was defined using constitutively active and dominant-negative c-Src expression constructs. c-Src-dependent modulation of matrix metalloproteinase-9 activity contributes significantly to the increased cellular invasiveness induced by CEACAM6 overexpression. Levels of CEACAM6 expression can modulate pancreatic adenocarcinoma cellular invasiveness in a c-Src-dependent manner. This pathway warrants further investigation as a target for therapy.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-10426397,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-10666389,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-10849312,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-11245487,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-11561605,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-11561606,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-11590190,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-11896570,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-12054612,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-12242156,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-12493242,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-12692724,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-12932673,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-12947321,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-14512395,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-14567964,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-14672761,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-14724575,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-14970613,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-15047698,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-1719635,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-7594554,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-7678982,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-8026879,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-8226872,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-8318403,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-8347297,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-8426746,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15316565-9632144
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
4
|
|
pubmed:volume |
91
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1384-90
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:15316565-Adenocarcinoma,
pubmed-meshheading:15316565-Animals,
pubmed-meshheading:15316565-Antigens, CD,
pubmed-meshheading:15316565-Antigens, Neoplasm,
pubmed-meshheading:15316565-Blotting, Western,
pubmed-meshheading:15316565-Cell Adhesion Molecules,
pubmed-meshheading:15316565-GPI-Linked Proteins,
pubmed-meshheading:15316565-Gene Expression Profiling,
pubmed-meshheading:15316565-Genes, src,
pubmed-meshheading:15316565-Humans,
pubmed-meshheading:15316565-Mice,
pubmed-meshheading:15316565-Mice, Nude,
pubmed-meshheading:15316565-Neoplasm Invasiveness,
pubmed-meshheading:15316565-Pancreatic Neoplasms,
pubmed-meshheading:15316565-RNA Interference,
pubmed-meshheading:15316565-Transplantation, Heterologous,
pubmed-meshheading:15316565-Tumor Cells, Cultured
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
CEACAM6 is a determinant of pancreatic adenocarcinoma cellular invasiveness.
|
|
pubmed:affiliation |
Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
